News

Sarepta Therapeutics stock sinks further Tuesday, after halting shipment of bestselling drug Elvidys
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Hoodline1d
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...
Investor's Business Daily on MSN3d
The FDA Will Reportedly Ask Sarepta To Stop Selling Elevidys. Shares Plummet.
Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...
Opendoor Technologies shares bounce again after turbulent trading
Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...
Stock market today: S&P 500 crosses 6,300, Nasdaq notches record with Big Tech set to take earnings spotlight
US stocks closed mixed on Monday, but the Nasdaq Composite and S&P 500 managed to notch fresh records. Wall Street began a ...
Forbes4y
Sarepta, Vertex, Neurocrine: There’s Deep Value In These ... - Forbes
Sarepta Therapeutics, a company that develops RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, has seen its stock decline by 54% year-to-date. The decline is due ...